Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Syros Pharmaceuticals Inc (NASDAQ: SYRS) closed the day trading at $0.36 down -86.85% from the previous closing price of $2.73. In other words, the price has decreased by -$86.85 from its previous closing price. On the day, 38.11 million shares were traded. SYRS stock price reached its highest trading level at $0.408 during the session, while it also had its lowest trading level at $0.35.
Ratios:
For a better understanding of SYRS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.25 and its Current Ratio is at 2.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on November 04, 2020, Upgraded its rating to Buy and sets its target price to $15 from $11 previously.
On September 22, 2020, Alliance Global Partners started tracking the stock assigning a Buy rating and target price of $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 11 ’24 when Chee Conley bought 50,000 shares for $1.71 per share. The transaction valued at 85,420 led to the insider holds 122,504 shares of the business.
Haas Jason bought 45,344 shares of SYRS for $76,006 on Sep 12 ’24. The Chief Financial Officer now owns 124,552 shares after completing the transaction at $1.68 per share. On Sep 10 ’24, another insider, Chee Conley, who serves as the President & CEO of the company, bought 50,000 shares for $1.51 each. As a result, the insider paid 75,260 and bolstered with 72,504 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRS now has a Market Capitalization of 73069424 and an Enterprise Value of 11583852. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.70. Its current Enterprise Value per Revenue stands at 30.01 whereas that against EBITDA is -0.105.
Stock Price History:
Over the past 52 weeks, SYRS has reached a high of $8.17, while it has fallen to a 52-week low of $1.43. The 50-Day Moving Average of the stock is -82.42%, while the 200-Day Moving Average is calculated to be -92.12%.
Shares Statistics:
Over the past 3-months, SYRS traded about 590.50K shares per day on average, while over the past 10 days, SYRS traded about 1420910 shares per day. A total of 26.45M shares are outstanding, with a floating share count of 19.70M. Insiders hold about 26.57% of the company’s shares, while institutions hold 55.95% stake in the company. Shares short for SYRS as of 1730332800 were 1248537 with a Short Ratio of 2.11, compared to 1727654400 on 999929. Therefore, it implies a Short% of Shares Outstanding of 1248537 and a Short% of Float of 5.06.
